After a high-profile clinical failure in 2016, investor interest in the much-hyped field of microbiome science chilled almost instantly. Now, however, the small but growing industry is starting to rebound.

Several key companies in the field, which focuses on manipulating microbes that are or ought to be in a person’s body, expect to report Phase 2 data by the end of this year, including the Somerville, Mass.-based Finch Therapeutics and a privately held French microbiome biotech, MaaT. Even bigger players in the field, Rebiotix and Seres Therapeutics (MCRB), are currently running pivotal studies — at least one of which should be fully enrolled by the middle of next year.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Informative but would have been nice to read details of close to IPO companies with micro biome products and their potential. Presenting only one analyst’s opinion fails to provide a balanced view of the field.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy